The influence of impaired salty taste thresholds and salt intake on annual decline of eGFR in patients with diabetes

The influence of impaired salty taste thresholds and salt intake on annual decline of eGFR in patients with diabetes - The impact of salty taste thresholds and salt intake on diabetic nephropathy

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000031607

Enrollment

250

Registered

2018-03-10

Start date

2017-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with type 1 and type 2 diabetes 2. Patients who signed the agreement with this study

Exclusion criteria

Exclusion criteria: 1. Patients with remarkable dysgeusia 2. Gestational diabetes mellitus and specific types of diabetes due to other causes 3. Patients with kidney disease, which is not associated with diabetes 4. Patients who are considered inappropriate by the attendant physician

Design outcomes

Primary

Measure	Time frame
To evaluate diet, exercise and life style, which might influence on the annual decline of renal function. We also evaluate clinical examinations below to find out the correlation between these variables and the decline of the renal function. eGFR, urinary albumin/ creatinine ratio, urinary liver-type fatty acid-binding protein, urinary N-acetyl-beta-D-glucosaminidase, urinary beta2-Microgrobulin, urinary adiponectin	—

Measure

Time frame

To evaluate diet, exercise and life style, which might influence on the annual decline of renal function. We also evaluate clinical examinations below to find out the correlation between these variables and the decline of the renal function. eGFR, urinary albumin/ creatinine ratio, urinary liver-type fatty acid-binding protein, urinary N-acetyl-beta-D-glucosaminidase, urinary beta2-Microgrobulin, urinary adiponectin

—

Countries

Japan

Contacts

Public ContactHiroyasu Mori

Tokushima University Diabetes Therapeutics and Research Center, Institute of Advanced Medical Sciences

mori.hiroyasu@tokushima-u.ac.jp088-633-7587

Outcome results